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Abstract: Solid lipid nanoparticles (SLNs) have been used for carrying different therapeutic 
agents because they improve absorption and bioavailability. The aim of the study was to prepare 
lipidic nanoparticles containing cyclosporine (CyA) by the emulsification-diffusion method and 
to study their physicochemical stability. Glyceryl behenate (Compritol ATO 888) and lauroyl 
macrogolglycerides (Gelucire 44/14) were used as carrier materials. Nanoparticles with good 
stability were obtained with Gelucire®, while it was difficult to obtain stable systems with 
Compritol®. Systems with Gelucire® were characterized by particle size, Z-potential, differential 
scanning calorimetry (DSC), scanning electron microscopy (SEM), entrapment efficiency and 
in vitro release. Particle size and Z-potential were evaluated for at least three months. With a 
high CyA content ($60 mg) in Gelucire SLNs, variations in size were greater and particle 
size also increased over time in all batches; this effect may have been caused by a probable 
expulsion of the drug due to the lipid’s partial rearrangement. While the Z-potential decreased 
10 mV after three months, this effect may be explained by the superficial properties of the 
drug that make the molecules to be preferably oriented at the solid-liquid interface, causing a 
change in the net charge of the particle. SEM confirmed size and shape of the nanoparticles. 
DSC studies evidenced that CyA affects the lipid structure by a mechanism still unknown. The 
entrapment efficiency was higher than 92%, and CyA release from SLNs was relatively fast 
(99.60% in 45 min).
Keywords: emulsification-diffusion method, solid lipid nanoparticles, glyceryl behenate, lauroyl 
macrogolglycerides, dispersion stability, cyclosporine
Introduction
In the 90s, a new type of carrier was developed, the so-called solid lipid nanoparticles 
(SLNs) which have been studied and modified from the original concept into more 
complex systems (eg, nanostructured lipid carriers or lipid-drug conjugate),1,2 but basi-
cally the usage of lipid materials to form the carrier has presented many advantages over 
other kinds of materials. Advances in this field of investigation are reported in literature 
mainly related to the method of production (eg, electrospray technique,3 coacervation),4 
the type of drug being encapsulated (eg, water soluble drugs,5 gene delivery),6 or the 
enhancement of bioavailability and absorption (eg, pentoxifylline,7 digoxin).8
SLNs are submicron-sized carriers composed of a lipid solid matrix stabilized 
by a surfactant. Such systems have some advantages over other colloidal carriers 
(nanoemulsions, microparticles, polymeric nanoparticles, liposomes, etc), such as low 
toxicity, high drug payload, capability of including lipophilic and hydrophilic drugs, 
drug targeting, controlled release (fast or sustained), and occlusive properties.9International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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SLNs can be produced by many methods, although the 
following are the most common: i) hot high pressure homog-
enization (HPH) technique and cold HPH technique; ii)   solvent 
emulsification/evaporation (SEE); iii) high shear homogeniza-
tion (HSH) and/or ultrasound, and iv) microemulsion.10
The most popular method is HPH; however, with both 
techniques (hot and cold), the drug, lipid, or other components 
may suffer chemical degradation due to the need of melting the 
lipid and/or to the increment of sample temperature during the 
process. Class I (highly toxic) or Class II (toxic) International 
Conference on Harmonization solvents are required to obtain 
SLNs by the SEE method, thus, its use is limited because of 
toxicological implications. With HSH and/or ultrasound, 
there is a broad particle size distribution and the product 
can be contaminated during the   ultrasonication step. These 
factors may lead to particle growth and physical instability. 
The microemulsion method has the disadvantage of requir-
ing high concentrations of surfactants and co-  surfactants, 
and a great quantity of water should be eliminated from the 
final product.
Recently, Quintanar-Guerrero et al10 proposed a modi-
fication of the emulsification-diffusion method (EDM) to 
prepare SLNs. In this modification, the author used a lipid 
instead of a preformed polymer. In general, a pre-emulsion 
is prepared; the internal phase contains the drug and the lipid 
which are solubilized in a partially water-miscible organic 
solvent, and the external phase is an aqueous solution of 
the stabilizer. This step can be performed with a cold or hot 
solvent, depending on the lipid’s solubility in the organic 
phase. Then, the solvent diffuses into the external phase 
when water is added to the system, causing the formation of 
nanoparticles (NP). The rest of the solvent can be eliminated 
by the use of techniques such as cross-flow filtration, or under 
reduced pressure.
In addition to the advantages mentioned before, 
one of the most interesting features of SLNs is that 
they can improve the absorption of various drugs, 
making them an attractive alternative for the adminis-
tration of substances with poor aqueous solubility and 
absorption.11−13
Cyclosporine (CyA) is a neutral, highly lipophilic 
unde  capeptide obtained from Tolypoclaudium inflatum and 
Cylindrocarpus lucidum, and is used as an immunosuppres-
sant drug to prevent transplant rejection. It is a Class II drug 
that has been studied in many pharmaceutical formulations 
due to its absorption and bioavailability problems.14−19 In 
recent years, SLNs containing CyA have been prepared 
using different preparation methods, optimized and studied 
by some research groups around the world.20−23 In this work 
EDM was used to prepare stable CyA-containing SLNs, 
showing an alternative to encapsulate this drug for the rea-
son that CyA has exhibited absorption and bioavailability 
problems since it was launched into the market, and such 
lipidic carriers may represent a good alternative to improve 
these parameters.2,24,25 In the preformulation phase of this 
study, we performed the EDM at room temperature (RT) for 
Gelucire 44/14, and at controlled temperature (65°C, CT) 
for Compritol 888 ATO. Only Gelucire® gave stable NP, 
so that systems with this lipid were characterized by their 
stability, particle size, Z-potential, morphology, thermal 
behavior, and entrapment efficiency. In the last phase of 
the study, in vitro drug release was evaluated, which is the 
first step of a further bioavailability study. Because of its 
adequate stability, this nanocarrier can be useful in further 
investigations for oral administration.
Materials and methods
Materials
CyA was a contribution from Moléculas Finas, SA de CV 
(DF, Mexico). Glyceryl behenate (Compritol ATO 888) 
and lauroyl macrogolglycerides (Gelucire 44/14) were 
provided by Lubrizol (Mexico City, Mexico). Polyvinyl 
alcohol (PVAL, Elvanol 5105) was obtained from Comercial 
Argento (DF, Mexico).
Distilled water was obtained from a Milli-Q station. 
Analytical grade ethyl acetate and methyl ethyl ketone 
(Fermont, Monterrey, NL, Mexico) were selected accord-
ing to their low toxicity. All other chemical reagents were 
of analytical grade.
Method of production of sLN
According to previous data (Quintanar-Guerrero, 2005),10 
stable SLNs were obtained with Gelucire® 44/14 or Com-
pritol® 888 ATO. Furthermore, the low toxicity and high 
biocompatibility of these materials are well known.
Preparation of sLNs at rT
The lipid used in this case was Gelucire 44/14, since it 
is soluble at RT in ethyl acetate, which was used as the 
internal phase in the pre-emulsification step. This partially 
water-miscible solvent was selected because in previous 
studies, stable particles of nanometric size were obtained. 
In this approach, at RT the amount of CyA was evaluated 
as variable, since the optimal amount of lipid, the type 
and amount of stabilizer, and the stirring rate have been 
defined in a previous study.10,26International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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The solvent and water were mutually saturated for 
10 min at RT in order to generate equilibrium between the 
two liquids. Variable amounts of CyA (20, 25, 30, 40, 60, 
120, and 200 mg) and 400 mg of lipid (Gelucire® 44/14) 
were weighted.
The drug and lipid were dissolved in 20 mL of water-
saturated solvent, which were emulsified with 40 mL of 
solvent-saturated aqueous solution containing 5% w/v of 
PVAL, using a mechanical stirrer (Caframo RZR-1; Ontario, 
Canada; propeller: PR 31; Heidolph, Schwabach, Germany) 
at 1,800 rpm for 10 min. Then, 160 mL of water (dilution 
medium) were added to allow the solvent to diffuse into 
the external phase, thus causing the aggregation of the lipid 
and the subsequent formation of SLNs. Finally, the solvent 
was eliminated from the sample by vacuum distillation at 
30°C and 70 mmHg. The remaining stabilizer and possible 
un-entrapped drug was removed by ultracentrifugation at 
30,000 rpm for 50 min (Beckman® Optimal LE-80K, CA, 
USA).
In this same way, empty SLNs and batches containing 
only CyA were prepared. All batches were produced in trip-
licate and the average size was immediately measured.
Preparation of sLNs at cT
In this case, we used Compritol for particle preparation, and 
heating was required to dissolve the lipid; therefore, keeping 
both phases at a CT (65°C that is lower than lipid’s melting 
point) during the entire process was a crucial factor to obtain 
a system with good characteristics. In general, 200 mg of lipid 
were weighted and dissolved in 20 mL of water-saturated 
solvent (methyl ethyl ketone). Variable amounts of CyA 
(5, 6, 8, and 10 mg) were added. This phase was emulsified 
with 40 mL of solvent-saturated aqueous solution containing 
5% w/v PVAL, using a mechanical stirrer at 1,400 rpm for 
10 min. Afterwards, 160 mL of water were added in order 
to cause the solvent diffusion to the continuous phase and 
to start the lipid aggregation and formation of NPs. Vacuum 
distillation was used to eliminate the solvent. PVAL and/
or any remaining drug were removed in the same way as 
described above. Also empty SLN were prepared. Each 
batch was prepared in triplicate, and the average size was 
evaluated.
characterization of the systems
Particle size analysis
The average size was determined by the dynamic light 
scattering technique (Coulter® N4, CA, USA). Each mea-
surement was obtained at a 90° fixed-angle for 180 s, at 
25°C, and the laser light wavelength (He/Ne, 10 mW) was 
set at 678 nm. A digital correlator was used to analyze the 
  scattering   intensity data under a unimodal analysis mode. 
All dispersions were diluted with distilled water until the 
light scattering signal (reported as counts per second) of the 
particles in suspension was within the instrument’s   sensitivity 
range. All batches prepared were measured in triplicate. Also, 
the macroscopic aspect of the systems was followed for 
six months in order to detect any instability signs and these 
results were corroborated with the information obtained in 
every analysis by dynamic light scattering technique.
Z-potential
Dispersions were diluted (1:10) with filtered water (0.22 µm 
pore). The electrophoretic mobility was transformed into 
Z-potential by applying the Smoluchowski approxima-
tion. Measurements were made in triplicate (Malvern 
  Instruments® NS ZEN 3600, Worcestershire, UK) at 25°C 
in a capillary cell.
scanning electron microscopy (seM)
After removing the excess stabilizer in the sample by two 
centrifugations (30,000 rpm/50 min) and following particle 
resuspension in water, a few drops of the dispersion were 
placed on a slab and dried under vacuum at RT. A Sputter 
Coater® JFC-1100 (JEOL, Tokyo, Japan) was used to coat 
the dried samples with gold (∼20 nm thickness), placing 
them onto stubs. Finally, the samples were observed under 
a JSM-6400® SEM (JEOL, Tokyo, Japan).
Differential scanning calorimetry (Dsc)
DSC measurements were carried out on the following samples: 
a) CyA; b) Gelucire® 44/14; c) PVAL; d) physical mixtures of 
CyA-Gelucire® (40, 80, and 200 mg of CyA with 400 mg of 
Gelucire in all cases); e) physical mixtures of CyA-PVAL 
(20, 80, and 200 mg of drug with 100 mg of PVAL in all 
cases); f) empty SLNs; g) batches containing only CyA (with-
out lipid); and h) batches with variable amounts of CyA (20, 
60, and 200 mg) and a constant amount of Gelucire® (400 mg). 
Batches containing only CyA were prepared in order to check 
if drug nanocrystals were formed. All samples were dried and 
stored in a desiccator at RT and standard humidity. Quantities 
between 3–6 mg of each sample were weighted. DSC studies 
were performed in a DSC Q10® (TA Instruments, DE, USA), 
using aluminum open pans. The heating rate was 10°C/min, 
with a temperature range of 0–230°C and a 50 mL/min nitro-
gen flow. Indium was used as the reference standard to check 
the calibration of the device.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Stabilizer quantification
The remaining amount of PVAL in SLNs was determined 
by a colorimetric method, based on the formation of a stable 
complex with iodine in the presence of boric acid.27 After 
lyophilizing an SLN dispersion (30 mg of drug with 400 mg 
of Gelucire®), about 10 mg of the sample were weighted and 
5 mL of ethanol were added. The sample was stirred for 24 h 
at RT. Then, 3 mL of distilled water were added and stir-
ring was continued for 3 h. Samples were filtered through a 
membrane (0.22 µm) and the volume was adjusted to 10 mL 
with distilled water. Then 5 mL were taken from this solution 
and mixed with 2 mL of 0.65 M boric acid and 1 mL of an 
iodine solution (0.05 M iodine and 0.15 M potassium iodide). 
The analysis was performed in triplicate. The absorbance of 
the resulting samples was measured at 640 nm (Varian® Cary 
IE 9531003   Spectrophotometer, Australia) and this result was 
interpolated in a calibration curve for PVAL (linear within the 
range of 5–50 µg/mL, R2 = 0.9993). A solution composed of 
5 mL of water, 2 mL of boric acid solution, and 1 mL of iodine 
solution was used as blank.
Drug loading and entrapment efficiency
Three batches with 400 mg of Gelucire® 44/14 and 30 mg of 
CyA were prepared at RT as described above and lyophilized, 
the reason for preparing this batch is because particle size 
had little variation and Z-potential had the highest value. 
A combination of 20 mg of lyophilized NP and 2 mL of 
ethanol were put into a beaker and were subsequently agitated 
for 24 h. After filtering the samples, 6,000 nL were applied 
on a reverse-phase plate to   perform the determination by high 
performance thin layer chromatography (HPTLC); mobile 
phase   acetonitrile-water (65:35) + 1% triethylamine, satu-
ration time 15 min, absorbance-reflection mode, deuterium 
lamp, λ = 240 nm). The results were interpolated in a cali-
bration curve which was linear within the range of 2–10 µg, 
R2 = 0.9950. The analysis was made in triplicate.
Equations (1) and (2) were applied to calculate drug 
loading (DL) and entrapment efficiency (EE):
DL
amountof CyAinlyophilized NPs
amountof lyophilized NPs
(%) =× 100 0  (1)
EE(%) =
DL(%)
% of the initial CyA content x
 (1-fraction of re esidual PVAL)
×100  (2)
It is important to introduce correction factor 1/(1-fraction 
of residual PVAL) to avoid an overestimation of the EE, due 
to the fact that during the SLN formation process, a certain 
amount of stabilizer remains on the carrier’s surface. The initial 
CyA content is the theoretical CyA loading in the batch.
In vitro release
A batch with 50 mg of CyA and 400 mg of Gelucire® was 
prepared as described previously and placed in a glass flask 
containing 10 mL of sodium lauryl sulfate (0.5% w/v aqueous 
solution). The stoppered flask was kept at 37°C in a water 
bath. Then, 2 mL samples were   withdrawn from the medium 
at 5, 15, 30, 45, and 60 min, and then at 2, 3, and 4 h, replac-
ing the medium with a fresh one at the same   temperature 
and introducing it through the same filter holder; in this 
way sink conditions were maintained during the test. The 
samples were withdrawn through a syringe adapted to a filter 
holder   (Swinnex® 13; Millipore, MA, USA) using IsoporeTM 
membrane filters (0.1 µm, VCTP; Millipore). Residual water 
was removed from each sample under reduced pressure, 
and then 2 mL of ethanol were added.   Following stirring 
(1 h), the samples were filtered and quantified by HPTLC, 
as mentioned before.
Turbidity measurement during in vitro release
Turbidity (τ) was measured in each sample taken during 
the release experiment, as a complementary test to follow 
up changes in particle size of SLNs in the medium with 
surfactant. The sample was placed in a quartz cell and was 
analyzed at 360 nm. Absorbance is related to τ by the next 
equation:28
 
τ=
2 303 .  A
l
  (3)
where l is the optical length (1 cm), and A is the absorbance.
Results
With both methods (at RT and CT), it was possible to obtain 
SLNs, unless there was a statistical difference in size for 
empty NP, P , 0.05 (Table 1).
During particle size evaluation on batches with 
Compritol®, a relatively rapid destabilization of the sys-
tems was evident, even with a lower CyA content (5 mg), 
leading to the presence of macroscopic agglomerates. The 
initial Z-potential (t = 0) was under 30 mV in all batches 
with Compritol®, and was associated with a low disper-
sion stability. Also, a higher particle size variation in SLN 
batches compared with   Gelucire® was observed. Based 
on these results, it was concluded that Compritol® is not 
adequate to produce CyA-SLNs, due to poor stability 
related problems.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Table 2 summarizes the composition and some charac-
terization results obtained for all the systems prepared with 
Gelucire®.
In the case of SLNs prepared with Gelucire®, the mac-
roscopic evaluation of the systems showed that the time of 
appearance of abundant and bigger agglomerates was shorter 
as the drug content in the dispersion increased ($60 mg 
CyA) (Table 2).
SEM showed that all batches evaluated had a solid matrix 
structure without crystal formation (Figure 1 A–D).
It was evident that alongside time the particles started a 
process of aggregation (Figure 1C and 1D), which could be 
confirmed with measurements of particle size (dynamic light 
scattering and visual appearance).
A calorimetric analysis was performed on free samples 
of Gelucire®, CyA, PVAL, physical mixtures (CyA-Gelucire 
and PVAL-CyA), and loaded and unloaded SLNs in order 
to determine the physical state of the drug and lipid, and to 
find out whether there were any interactions between them. 
Figures 2, 3 and 4 show the thermograms obtained. Figure 2 
shows the thermal events of raw materials. Enthalpy of fusion 
of the drug is at 128.5°C. The first peak of Gelucire® at 
40.6°C is attributable to the fusion of the major proportion 
of glycerides, and the endotherm at 136.88°C corresponds to 
minority components of the mixture of glycerides. For PVAL 
the   thermal events corresponding to its glass transition are 
shown. The physical mixtures analyzed are shown in Figure 3. 
For physical mixtures CyA-Gelucire® we observed any peak 
corresponding to crystal melting of drug, and no changes 
are observed in enthalpy fusion of Gelucire® (around 40°C 
in the three physical mixtures). An effect of drug amount is 
observed in physical mixtures CyA-PVAL; as drug increases 
in the physical mixture it is more evident its melting point. 
Thermal events of all batches analyzed are shown in Figure 
4. None of them showed the peak corresponding to crystal 
melting of the drug and Gelucire® peak (40.6°C) showed less 
sharpness at t = 0 with high drug amounts in the SLN batches, 
suggesting that CyA somehow affected lipid’s structure.
The in vitro release results and the turbidity measurement 
are shown in Figure 5.
The remaining PVAL quantified in the formulation 
Gelucire®-CyA (400:30 mg) was 4.37% ± 0.08 (n = 3). 
The residual PVAL for polymeric NPs is reported to be 
proximately 2%–4%,29 so it can be concluded that purifica-
tion process of the dispersion was adequate.
In Table 2 the results for encapsulation efficiency are 
shown. In all systems these values were greater than 92%.
Discussion
As was stated before, a relatively rapid destabilization 
was evident during particle size evaluation on batches 
with   Compritol®, even with a lower CyA content (5 mg), 
leading to the presence of macroscopic agglomerates at the 
second day of analysis. Comparing the quantity of drug 
Table  1  Mean  particle  size  of  empty  sLNs  prepared  at  rT 
(gelucire® = 400 mg) and at cT (compritol® = 200 mg), with 
5% w/v PVAL; n = 3
Mean particle size (nm) and  
polydispersity index
Gelucire® Compritol®
Batch 1 280.0 [0.220] 789.0 [0.524]
Batch 2 281.3 [0.283] 756.9 [0.509]
Batch 3 280.8 [0.316] 734.5 [0.481]
Mean  280.7a 760.1a
standard deviation (σ) 0.65 27.30
Notes: aexists statistical difference between means, P , 0.05; PDI values between 
brackets.
Table 2 composition of the formulations, percentage (w/w) of cyA with respect to the weight of lipid, mean particle size, Z-potential 
and probable day of aggregation of sLNs prepared at rT (gelucire®) with 5% w/v PVAL
System  Gelucire  
(mg)
CyA  
(mg)
% CyA  
(w/w)
Particle size  
(nm)a
Z-potential 
(mV)a
Day of visible  
aggregation
Encapsulation   
efficiency (%)
empty sLN 400 0 0.00 276.6 ± 5 [0.34] 23.70 ± 0.034 – –
Batches containing  
only cyA
0 40 0.00 2510.0 ± 7 [0.87] 22.50 ± 0.196 11 –
A 400 20 5.00 256.4 ± 1 [0.36] 22.80 ± 0.014 69 99.18
B 400 25 6.25 346.1 ± 3 [0.28] 33.07 ± 0.024 80 99.15
c 400 30 7.50 310.5 ± 3 [0.22] 39.50 ± 0.150 64 99.13
D 400 40 10.00 248.3 ± 5 [0.15] 28.91 ± 1.257 78 99.02
e  400 50 12.50 320.8 ± 7 [0.18] 30.11 ± 1.361 20 98.45
F 400 60 15.00 459.3 ± 1 [0.48] 30.50 ± 0.032 12 98.19
g  400 120 30.00 375.7 ± 1 [0.65] 34.12 ± 0.048 4 95.26
h  400 200 50.00 478.3 ± 1 [0.73] 30.13 ± 3.841 2 92.74
Notes: areported as mean ± standard deviation; n  = 3.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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that Compritol® SLNs can carry with that of Gelucire®, it 
can be assumed that chemical composition (higher content 
of hydrophobic and longer chain length, .83% C22) and 
the high degree of crystallinity of the former could lead to 
drug expulsion from the NP easily. In this respect, Varia 
et al22 corroborate that chemical composition of the lipid 
has an important effect to incorporate drugs in SLNs; a lipid 
which is formed mainly by structurally similar molecules 
cannot accommodate big quantities of drug compared with 
a lipid which is a mixture of mono-, di- and triglycerides, 
and has the ability to offer many imperfections to incor-
porate the drugs.
When comparing the mean particle size of NP prepared 
with Gelucire® with that of NP prepared with Compritol® 
(Table 1), the former had a smaller size. This can be attributed 
to the complex mixtures of mono-, di-, and triglycerides that 
formed both materials; however, Gelucire® has a higher con-
tent of short hydrophilic chains [C8, C10, C12 (30%–50%), 
C14 (5%–25%), C18 (5%–35%)] than Compritol® [C16, 
C18, C20 (,10%), C22 (.83%), C24 (,3%)]. For this 
reason, the higher content of hydrophobic and longer chains 
in Compritol® may somehow hinder its dispersion in aqueous 
media, compared with Gelucire®.
The initial Z-potential (t = 0) was under 30 mV in all 
batches with Compritol®, and was associated with a low 
dispersion stability. Also, the higher particle size variation 
in SLN batches compared with Gelucire® was determinant 
to conclude that Compritol® was not adequate to produce 
CyA-SLNs, due to poor stability related problems.
The presence of bigger and abundant agglomerates 
in systems prepared with Gelucire® was more evident 
with DL . 10% and also the time of appearance of these 
  agglomerates were developed in shorter time (Table 2). This 
A
B
C
D
Figure  1  scanning  electron  micrographs  of  loaded  gelucire®  44/14  sLNs  with 
different theoretical loadings (bar = 1 µm). A) cyA-gelucire® (20:400 mg; 5% cyA) 
t = 0; B) cyA-gelucire® (40:400 mg; 10% cyA) t = 0; C) cyA-gelucire® (30:400 mg; 
7.5% cyA) t = 0; D) cyA-gelucire® (30:400 mg; 7.5% cyA) t = 4 months.
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effect may have been caused by a probable expulsion of the 
drug due to the lipid’s partial rearrangement. It is well known 
that glycerides have three main polymorphs: α, β’ and β. 
Assuming that our NP were made from a material contain-
ing mono-, di-, and triglycerides (proportions: [C8, C10, 
C12 (30%–50%), C14 (5%–25%), C18 (5%–35%)]), it is 
possible to believe that, during storage, a part of the lipid 
matrix transformed from one polymorph into another, reduc-
ing the spaces in the matrix and causing the drug to come 
out. Several reports have described this behavior.1,30–32 Once 
the CyA molecules were outside or on the nanoparticle’s 
surface, they started to interact inter- or intramolecularly, 
producing associations between them and causing a physical 
stability loss, although SEM studies did not confirm crystal 
deposition on SLN surface.
For the dispersions with 25 mg of CyA, the Z-potential 
was higher than 30 mV (Table 2), which is related to a com-
plete electrostatic stabilization of particles in suspension, 
with a maximum value of 39.50 mV for a CyA content of 
30 mg. When the dispersion had more than 30 mg of drug, 
the Z-potential did not show a specific trend. This effect 
may be explained by the superficial properties of the drug 
that make the molecules to be preferably oriented at the 
solid-liquid interface, causing a change in the net charge of 
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Figure  3  Dsc  thermograms  of  A)  Physical  mixture  of  cyA-gelucire®  (40:400 
mg  w/w);  B)  Physical  mixture  of  cyA-gelucire®  (80:400  mg  w/w);  c)  Physical 
mixture of cyA-gelucire® (200:400 mg w/w); D) Physical mixture of cyA-PVAL 
(20:100 mg w/w); e) Physical mixture of cyA-PVAL (80:100 mg w/w); and F) Physical 
mixture of cyA-PVAL (200:100 mg w/w).
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Figure 4 Dsc thermograms of A) and B) batches prepared with cyA only, t = 0 
and t = 5 months respectively; c) and D) empty sLNs; t = 0 and t = 5 months 
respectively; e) and F) sLNs with 5% cyA (drug-lipid ratio 20:400 (w/w)), t = 0 
and t = 5.5 months, respectively; g) and h) sLNs with 15% cyA (drug-lipid ratio 
60:400 (w/w)), t = 0 and t = 5.5 months, respectively; I) and J) sLNs with 50% cyA 
(drug-lipid ratio 200:400 (w/w)), t = 0 and t = 5.5 months, respectively.
the particle. We may have expected a direct increase of the 
charge for a higher drug content, but this behavior was not 
observed, probably because CyA can be located inside and/or 
outside the NP; in this respect, Lechuga-Ballesteros et al33 
have recently reported that CyA can form a liquid crystal 
structure in repeated layers.
After three months of storage, the Z-potential decreased by 
almost 10 mV for all dispersions prepared with Gelucire®. This 
fact can be explained by the partial and gradual arrangement of 
the lipid, and by the ejection of small amounts of CyA. In the 
latter case, the CyA molecules outside the NP may induce the 
formation of the aforementioned structures, thus changing the 
net charge of the particle. Also, the production method may 
provide another explanation. Following dispersion produc-
tion, the molecules have not a specific arrangement, they are 
randomly arrayed all over the nanoparticle; however, CyA 
molecules may acquire a more ordered distribution in space 
over time33 which can change the surface charge.
SEM showed that all batches evaluated had a solid matrix 
structure without crystal formation (Figure 1A–1C) and 
alongside time showed the aggregation of NP (Figure 1D); International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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this fact can be explained by changes in the particles’ charge 
by the ejection of small amounts of the drug or by the 
  rearrangement of CyA molecules to a more ordered state 
after production of SLNs.
Thermograms are shown in Figure 2, 3, and 4. An endo-
therm at 128.5°C was shown for pure CyA; this event was 
not observed for batches containing only CyA (40 mg) at 
t = 0 and t = five months (Figure 4A and 4B), and it may 
be related to a low drug amount in the sample, because in 
the CyA-PVAL physical mixtures analyzed, the endotherm 
corresponding to the melting process of the drug could 
only be observed from 80 mg of CyA (Figure 3E). Melting 
point of drug in these physical mixtures did not change 
(around 128°C).
DSC thermograms of empty SLNs at t = 0 and t = five 
months did not show any change in thermal events 
(Figure 4C and 4D). It is possible that hydroxyl groups of 
glycerides can form hydrogen bonds with hydroxyl groups of 
PVAL, avoiding lipid crystallization. In the batches of SLN 
containing 5, 15, and 50% of drug (20, 60, and 200 mg), there 
was no endothermic peak corresponding to crystal melting, 
even at five months, suggesting the presence of a molecu-
lar dispersion of the drug and lipid. Furthermore, it can be 
assumed that CyA maintained an amorphous or disordered 
crystalline phase of a molecular dispersion or a solid solution 
state in the lipid matrix after the process, as reported previ-
ously by our group for triclosan-containing polymeric NP,29 
and for CyA-loaded SLNs.21
Thermograms of CyA-PVAL physical mixtures with 
80 and 200 mg of drug (Figure 3E and 3F) showed the 
endothermic peak corresponding to the melting of CyA; 
thus, the absence of an endotherm in the thermogram of the 
batch containing 200 mg of drug (Figure 4I and 4J)   supports 
our assumption regarding the formation of a molecular 
dispersion.
Another important event is that observed for the 
  endotherm associated to Gelucire® melting. At t = 0, this 
endotherm was sharper than at five months (Figure 4E–4J); 
in fact, it was not clearly detected at this time point. During 
the SLN formation process, the solvent diffuses from the 
emulsion’s globules; the drug and lipid aggregate randomly, 
possibly leaving regions of free lipid with a high order 
or crystalline state. The drug and lipid may interact over 
time, and some CyA molecules may be inserted between 
the glyceride chains,21 reducing the crystalline state of the 
lipid. On the other hand, it was noteworthy that the   Gelucire® 
peak (40.6°C) showed less sharpness at t = 0 with high drug 
amounts in the SLN batches, suggesting first that CyA was 
encapsulated into the NPs and second, that the drug had an 
important impact on the lipid’s structure. This behavior is 
similar to that reported in model lipidic membranes, in which 
the peptide is considered as a “defect” in the lipid bilayer, 
which can be randomly distributed in the hydrocarbon region, 
affecting lipid interactions due to the electrostatic charges 
and to the geometry of the guest molecule.34,35
An immediate release was observed (Figure 5); 99.60% 
of CyA was released from the SLN at 45 min, indicating the 
presence of an amorphous structure of the lipid and maybe 
the existence of CyA molecules on the NP surface, which 
allows a rapid dissolution and possibly higher loadings.
Turbidity measurement (Figure 5) is an indirect way to 
determine changes of particle size in the dispersion once 
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solid lipid nanoparticles containing cyclosporine
it enters the biological fluids. In this experiment, turbidity 
decreased over time due to the reduction of entire nano-
spheres owing to the action of the dissolution medium.
The great advantage of using Gelucire®, composed of a 
mixture of mono-, di-, and triglycerides with different chain 
lengths, is that the matrix may have more imperfections 
in which higher quantities of drug can accommodate, in 
contrast with the reduced spaces provided by structurally 
similar molecules (for example tripalmitin and tristearin). 
This feature was also important to achieve high EE, .92% 
(Table 2). Moreover, the possibility of an amorphous state 
in the lipidic matrix could be responsible for the amount of 
drug encapsulated. High EE were also found using different 
preparation methods of SLNs.20,22,23
Conclusion
With the EDM, it was possible to obtain Gelucire® NP with 
a good stability. Although NP with Compritol® were also 
  prepared, the significant instability issues at the first stages of 
storage made this material inadequate to obtain such carriers.
As the CyA content increased in Gelucire® NP, variations 
in size were more evident and particle size increased over time 
in all batches. The Z-potential decreased 10 mV after three 
months in SLNs prepared with Gelucire®. The   formation of 
molecular dispersions was evident, and it was shown that CyA 
affected the lipid’s structure by a mechanism still unknown, 
probably by the ability of these molecules to form a liquid 
crystal with a repeated-layer structure. High EE was achieved 
(.92%). CyA release from SLNs was relatively fast (99.60% 
in 45 min), in association with a rapid dissolution due to the 
presence of many imperfections in lipid structure. We are still 
working on the evaluation of these carriers, since they may 
have a great impact on CyA’s bioavailability profile as a result 
of a dissolution improvement because of the imperfections 
of the lipidic matrix.
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